Inhibition of RhoA, as well as activation of Rac1, restored hypertensive PAECs' phenotype to normal, infatuating the eventual role of RhoA/ROCK pathway modulation as an alternative therapy for PPHN (102). The gene discussed is RAC1; the disease is persistent fetal circulation syndrome.